Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging t...
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
Elsevier
2021
|
| _version_ | 1826267618320842752 |
|---|---|
| author | Liu, C Ginn, HM Dejnirattisai, W Supasa, P Wang, B Tuekprakhon, A Nutalai, R Zhou, D Mentzer, AJ Zhao, Y Duyvesteyn, HME López-Camacho, C Slon-Campos, J Walter, TS Skelly, D Johnson, SA Ritter, TG Mason, C Costa Clemens, SA Gomes Naveca, F Nascimento, V Nascimento, F Fernandes da Costa, C Resende, PC Pauvolid-Correa, A Siqueira, MM Dold, C Temperton, N Dong, T Pollard, AJ Knight, JC Crook, D Lambe, T Clutterbuck, E Bibi, S Flaxman, A Bittaye, M Belij-Rammerstorfer, S Gilbert, SC Malik, T Carroll, MW Klenerman, P Barnes, E Dunachie, SJ Baillie, V Serafin, N Ditse, Z Da Silva, K Paterson, NG Williams, MA Goulder, P Fry, EE Ren, J Stuart, DI Screaton, GR |
| author_facet | Liu, C Ginn, HM Dejnirattisai, W Supasa, P Wang, B Tuekprakhon, A Nutalai, R Zhou, D Mentzer, AJ Zhao, Y Duyvesteyn, HME López-Camacho, C Slon-Campos, J Walter, TS Skelly, D Johnson, SA Ritter, TG Mason, C Costa Clemens, SA Gomes Naveca, F Nascimento, V Nascimento, F Fernandes da Costa, C Resende, PC Pauvolid-Correa, A Siqueira, MM Dold, C Temperton, N Dong, T Pollard, AJ Knight, JC Crook, D Lambe, T Clutterbuck, E Bibi, S Flaxman, A Bittaye, M Belij-Rammerstorfer, S Gilbert, SC Malik, T Carroll, MW Klenerman, P Barnes, E Dunachie, SJ Baillie, V Serafin, N Ditse, Z Da Silva, K Paterson, NG Williams, MA Goulder, P Fry, EE Ren, J Stuart, DI Screaton, GR |
| author_sort | Liu, C |
| collection | OXFORD |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations. |
| first_indexed | 2024-03-06T20:56:58Z |
| format | Journal article |
| id | oxford-uuid:3995f1ac-4fdb-4dba-8aec-a3c9513a2db6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:56:58Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:3995f1ac-4fdb-4dba-8aec-a3c9513a2db62022-03-26T13:56:33ZReduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3995f1ac-4fdb-4dba-8aec-a3c9513a2db6EnglishSymplectic ElementsElsevier2021Liu, CGinn, HMDejnirattisai, WSupasa, PWang, BTuekprakhon, ANutalai, RZhou, DMentzer, AJZhao, YDuyvesteyn, HMELópez-Camacho, CSlon-Campos, JWalter, TSSkelly, DJohnson, SARitter, TGMason, CCosta Clemens, SAGomes Naveca, FNascimento, VNascimento, FFernandes da Costa, CResende, PCPauvolid-Correa, ASiqueira, MMDold, CTemperton, NDong, TPollard, AJKnight, JCCrook, DLambe, TClutterbuck, EBibi, SFlaxman, ABittaye, MBelij-Rammerstorfer, SGilbert, SCMalik, TCarroll, MWKlenerman, PBarnes, EDunachie, SJBaillie, VSerafin, NDitse, ZDa Silva, KPaterson, NGWilliams, MAGoulder, PFry, EERen, JStuart, DIScreaton, GRSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations. |
| spellingShingle | Liu, C Ginn, HM Dejnirattisai, W Supasa, P Wang, B Tuekprakhon, A Nutalai, R Zhou, D Mentzer, AJ Zhao, Y Duyvesteyn, HME López-Camacho, C Slon-Campos, J Walter, TS Skelly, D Johnson, SA Ritter, TG Mason, C Costa Clemens, SA Gomes Naveca, F Nascimento, V Nascimento, F Fernandes da Costa, C Resende, PC Pauvolid-Correa, A Siqueira, MM Dold, C Temperton, N Dong, T Pollard, AJ Knight, JC Crook, D Lambe, T Clutterbuck, E Bibi, S Flaxman, A Bittaye, M Belij-Rammerstorfer, S Gilbert, SC Malik, T Carroll, MW Klenerman, P Barnes, E Dunachie, SJ Baillie, V Serafin, N Ditse, Z Da Silva, K Paterson, NG Williams, MA Goulder, P Fry, EE Ren, J Stuart, DI Screaton, GR Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| title | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| title_full | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| title_fullStr | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| title_full_unstemmed | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| title_short | Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum |
| title_sort | reduced neutralization of sars cov 2 b 1 617 by vaccine and convalescent serum |
| work_keys_str_mv | AT liuc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT ginnhm reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT dejnirattisaiw reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT supasap reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT wangb reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT tuekprakhona reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT nutalair reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT zhoud reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT mentzeraj reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT zhaoy reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT duyvesteynhme reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT lopezcamachoc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT sloncamposj reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT walterts reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT skellyd reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT johnsonsa reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT rittertg reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT masonc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT costaclemenssa reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT gomesnavecaf reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT nascimentov reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT nascimentof reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT fernandesdacostac reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT resendepc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT pauvolidcorreaa reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT siqueiramm reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT doldc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT tempertonn reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT dongt reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT pollardaj reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT knightjc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT crookd reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT lambet reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT clutterbucke reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT bibis reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT flaxmana reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT bittayem reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT belijrammerstorfers reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT gilbertsc reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT malikt reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT carrollmw reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT klenermanp reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT barnese reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT dunachiesj reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT bailliev reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT serafinn reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT ditsez reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT dasilvak reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT patersonng reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT williamsma reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT goulderp reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT fryee reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT renj reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT stuartdi reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum AT screatongr reducedneutralizationofsarscov2b1617byvaccineandconvalescentserum |